This study is the first in the Turkish population in which serum GAL-1, -3, and − 8 levels were clinically evaluated together in glioma pathologies with high angiogenic activity and sheds light on the role of increased serum galectin levels in the promotion of low-grade tumors to high-grade tumors. The gene discussed is LGALS1; the disease is central nervous system cancer.